Materias dentro de su búsqueda.
Materias dentro de su búsqueda.
-
4101por Sweileh, Waleed M.“…The main funding sponsors were the National Institute of Health. Pfizer, Merck, and Bayer pharmaceutical companies played a key role in funding AMS research. …”
Publicado 2021
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
4102por Jangra, Sonia, Ye, Chengjin, Rathnasinghe, Raveen, Stadlbauer, Daniel, Krammer, Florian, Simon, Viviana, Martinez-Sobrido, Luis, García-Sastre, Adolfo, Schotsaert, Michael“…In addition, we included sera from five individuals who received two doses of the Pfizer SARS-CoV-2 vaccine BNT162b2. Serum neutralization efficiency was lower against the E484K rSARS-CoV-2 (vaccination samples: 3.4 fold; convalescent low IgG: 2.4 fold, moderate IgG: 4.2 fold and high IgG: 2.6 fold) compared to USA-WA1/2020. …”
Publicado 2021
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
4103“…Vaccine efficacy against symptomatic disease was assumed to be 88% on the basis of Pfizer-BioNTech and Oxford-AstraZeneca vaccines being administered in the UK, and protection against infection was varied from 0% to 85%. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
4104por Vasileiou, Eleftheria, Simpson, Colin R, Shi, Ting, Kerr, Steven, Agrawal, Utkarsh, Akbari, Ashley, Bedston, Stuart, Beggs, Jillian, Bradley, Declan, Chuter, Antony, de Lusignan, Simon, Docherty, Annemarie B, Ford, David, Hobbs, FD Richard, Joy, Mark, Katikireddi, Srinivasa Vittal, Marple, James, McCowan, Colin, McGagh, Dylan, McMenamin, Jim, Moore, Emily, Murray, Josephine LK, Pan, Jiafeng, Ritchie, Lewis, Shah, Syed Ahmar, Stock, Sarah, Torabi, Fatemeh, Tsang, Ruby SM, Wood, Rachael, Woolhouse, Mark, Robertson, Chris, Sheikh, Aziz“…BACKGROUND: The BNT162b2 mRNA (Pfizer–BioNTech) and ChAdOx1 nCoV-19 (Oxford–AstraZeneca) COVID-19 vaccines have shown high efficacy against disease in phase 3 clinical trials and are now being used in national vaccination programmes in the UK and several other countries. …”
Publicado 2021
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
4105por Broseta, José Jesús, Rodríguez-Espinosa, Diana, Rodríguez, Néstor, Mosquera, María del Mar, Marcos, María Ángeles, Egri, Natalia, Pascal, Mariona, Soruco, Erica, Bedini, José Luis, Bayés, Beatriu, Maduell, Francisco“…EXPOSURE: Immunization with either the mRNA-1273 (Moderna) or BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 mRNA vaccine. OUTCOME: Seroconversion, defined as the detection of IgG antibodies to the receptor-binding domain of the S1 spike antigen of SARS-CoV-2 (anti–S1-RBD IgG), and the identification of activated CD4(+) T cells 3 weeks after completing vaccination. …”
Publicado 2021
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
4106por Pawlowski, Colin, Lenehan, Patrick, Puranik, Arjun, Agarwal, Vineet, Venkatakrishnan, A.J., Niesen, Michiel J.M., O’Horo, John C., Virk, Abinash, Swift, Melanie D., Badley, Andrew D., Halamka, John, Soundararajan, Venky“…BACKGROUND: Two US Food and Drug Administration (FDA)-authorized coronavirus disease 2019 (COVID-19) mRNA vaccines, BNT162b2 (Pfizer/BioNTech) and mRNA-1273 (Moderna), have demonstrated high efficacy in large phase 3 randomized clinical trials. …”
Publicado 2021
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
4107“…The trust emotion reached its peak on November 9, 2020, when Pfizer announced that its vaccine is 90% effective. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
4108por Brosh-Nissimov, Tal, Orenbuch-Harroch, Efrat, Chowers, Michal, Elbaz, Meital, Nesher, Lior, Stein, Michal, Maor, Yasmin, Cohen, Regev, Hussein, Khetam, Weinberger, Miriam, Zimhony, Oren, Chazan, Bibiana, Najjar, Ronza, Zayyad, Hiba, Rahav, Galia, Wiener-Well, Yonit“…METHODS: A retrospective multicentre cohort study of 17 hospitals included patients fully vaccinated with Pfizer/BioNTech's BNT162b2 vaccine who developed COVID-19 more than 7 days after the second vaccine dose and required hospitalization. …”
Publicado 2021
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
4109por Demonbreun, Alexis R., Sancilio, Amelia, Velez, Matt P., Ryan, Daniel T., Saber, Rana, Vaught, Lauren A., Reiser, Nina L., Hsieh, Ryan R., D'Aquila, Richard T., Mustanski, Brian, McNally, Elizabeth M., McDade, Thomas W.“…Participants were analysed before and after mRNA vaccination (BNT162b2/Pfizer or mRNA-1273/Moderna) in a community-based, home-collected, longitudinal serosurvey in the Chicago area (USA); none reported hospitalization for COVID-19. …”
Publicado 2021
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
4110por Cocco, Giulio, Delli Pizzi, Andrea, Fabiani, Stefano, Cocco, Nino, Boccatonda, Andrea, Frisone, Alessio, Scarano, Antonio, Schiavone, Cosima“…We found no significant differences between the three COVID-19 vaccines: the Pfizer/BioNTech BNT162b2 mRNA vaccine, the AstraZeneca ChAdOx1 vaccine and Moderna’s mRNA-1273 vaccine. …”
Publicado 2021
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
4111“…Nevertheless, a further detailed analysis must be conducted on the adverse thrombotic manifestations following adenoviral-based COVID-19 vaccines (J&J, AstraZeneca) compared to mRNA-based vaccines (Moderna, Pfizer) to assess causality with higher specificity.…”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
4112por Klugar, Miloslav, Riad, Abanoub, Mekhemar, Mohamed, Conrad, Jonas, Buchbender, Mayte, Howaldt, Hans-Peter, Attia, Sameh“…We aimed in this study to report for the first time the short-term side effects following mRNA-based (Pfizer-BioNTech and Moderna) and viral vector-based (AstraZeneca) COVID-19 vaccines among German healthcare workers. …”
Publicado 2021
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
4113por Suhandynata, Raymond T, Bevins, Nicholas J, Tran, Jenny T, Huang, Deli, Hoffman, Melissa A, Lund, Kyle, Kelner, Michael J, McLawhon, Ronald W, Gonias, Steven L, Nemazee, David, Fitzgerald, Robert L“…METHODS: The ability of 4 commercial SARS-CoV-2 serology platforms to detect previous infection or vaccination were evaluated using a cohort of 53 patients who were SARS-CoV-2 PCR positive, 89 SARS-CoV-2-vaccinated healthcare workers (Pfizer or Moderna), and 127 patients who were SARS-CoV-2 negative. …”
Publicado 2021
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
4114por Touré, F., Danthu, C., Hantz, S., Duval, M., El Ouafi, Z., Allot, V., Bocquentin, F., Rerolle, J.P., Alain, S.“…DESCRIPTION: We investigated early serological response after COVID 19 vaccination with Pfizer/BioNTech (BNT162b2) mRNA vaccine in groups of patients undergoing hemodialysis (n = 78), kidney transplant recipients (n = 74), and in healthy controls. …”
Publicado 2021
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
4115por Krzywicka, Katarzyna, Heldner, Mirjam R., Sánchez van Kammen, Mayte, van Haaps, Thijs, Hiltunen, Sini, Silvis, Suzanne M., Levi, Marcel, Kremer Hovinga, Johanna A., Jood, Katarina, Lindgren, Erik, Tatlisumak, Turgut, Putaala, Jukka, Aguiar de Sousa, Diana, Middeldorp, Saskia, Arnold, Marcel, Coutinho, Jonathan M., Ferro, José M.“…RESULTS: In all, 213 CVST cases were identified: 187 after AstraZeneca/Oxford (ChAdOx1 nCov‐19) vaccination and 26 after a messenger RNA (mRNA) vaccination (25 with Pfizer/BioNTech, BNT162b2, and one with Moderna, mRNA‐1273). …”
Publicado 2021
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
4116por Thomas, Stephen J., Moreira, Edson D., Kitchin, Nicholas, Absalon, Judith, Gurtman, Alejandra, Lockhart, Stephen, Perez, John L., Pérez Marc, Gonzalo, Polack, Fernando P., Zerbini, Cristiano, Bailey, Ruth, Swanson, Kena A., Xu, Xia, Roychoudhury, Satrajit, Koury, Kenneth, Bouguermouh, Salim, Kalina, Warren V., Cooper, David, Frenck, Robert W., Hammitt, Laura L., Türeci, Özlem, Nell, Haylene, Schaefer, Axel, Ünal, Serhat, Yang, Qi, Liberator, Paul, Tresnan, Dina B., Mather, Susan, Dormitzer, Philip R., Şahin, Uğur, Gruber, William C., Jansen, Kathrin U.“…(Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.)…”
Publicado 2021
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
4117por Chemaitelly, Hiam, Tang, Patrick, Hasan, Mohammad R., AlMukdad, Sawsan, Yassine, Hadi M., Benslimane, Fatiha M., Al Khatib, Hebah A., Coyle, Peter, Ayoub, Houssein H., Al Kanaani, Zaina, Al Kuwari, Einas, Jeremijenko, Andrew, Kaleeckal, Anvar H., Latif, Ali N., Shaik, Riyazuddin M., Abdul Rahim, Hanan F., Nasrallah, Gheyath K., Al Kuwari, Mohamed G., Al Romaihi, Hamad E., Butt, Adeel A., Al-Thani, Mohamed H., Al Khal, Abdullatif, Bertollini, Roberto, Abu-Raddad, Laith J.“…The persistence of BNT162b2 (Pfizer–BioNTech) vaccine effectiveness against infection and disease in Qatar, where the B.1.351 (or beta) and B.1.617.2 (or delta) variants have dominated incidence and polymerase-chain-reaction testing is done on a mass scale, is unclear. …”
Publicado 2021
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
4118por Atmar, Robert L., Lyke, Kirsten E., Deming, Meagan E., Jackson, Lisa A., Branche, Angela R., El Sahly, Hana M., Rostad, Christina A., Martin, Judith M., Johnston, Christine, Rupp, Richard E., Mulligan, Mark J., Brady, Rebecca C., Frenck, Robert W., Bäcker, Martín, Kottkamp, Angelica C., Babu, Tara M., Rajakumar, Kumaravel, Edupuganti, Srilatha, Dobryzynski, David, Posavad, Christine M., Archer, Janet I., Crandon, Sonja, Nayak, Seema U., Szydlo, Daniel, Zemanek, Jillian, Dominguez Islas, Clara P., Brown, Elizabeth R., Suthar, Mehul S., McElrath, M. Juliana, McDermott, Adrian B., O’Connell, Sarah E., Montefiori, David C., Eaton, Amanda, Neuzil, Kathleen M., Stephens, David S., Roberts, Paul C., Beigel, John H.“…METHODS: In this phase 1/2 open-label clinical trial conducted at ten U.S. sites, adults who received one of three EUA Covid-19 vaccines at least 12 weeks prior to enrollment and had no reported history of SARS-CoV-2 infection received a booster injection with one of three vaccines (Moderna mRNA-1273 100-μg, Janssen Ad26.COV2.S 5×10(10) virus particles, or Pfizer-BioNTech BNT162b2 30-μg; nine combinations). …”
Publicado 2021
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
4119por Mevorach, Dror, Anis, Emilia, Cedar, Noa, Bromberg, Michal, Haas, Eric J., Nadir, Eyal, Olsha-Castell, Sharon, Arad, Dana, Hasin, Tal, Levi, Nir, Asleh, Rabea, Amir, Offer, Meir, Karen, Cohen, Dotan, Dichtiar, Rita, Novick, Deborah, Hershkovitz, Yael, Dagan, Ron, Leitersdorf, Iris, Ben-Ami, Ronen, Miskin, Ian, Saliba, Walid, Muhsen, Khitam, Levi, Yehezkel, Green, Manfred S., Keinan-Boker, Lital, Alroy-Preis, Sharon“…BACKGROUND: Approximately 5.1 million Israelis had been fully immunized against coronavirus disease 2019 (Covid-19) after receiving two doses of the BNT162b2 messenger RNA vaccine (Pfizer–BioNTech) by May 31, 2021. After early reports of myocarditis during adverse events monitoring, the Israeli Ministry of Health initiated active surveillance. …”
Publicado 2021
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
4120por Edelman-Klapper, Hadar, Zittan, Eran, Bar-Gil Shitrit, Ariella, Rabinowitz, Keren Masha, Goren, Idan, Avni-Biron, Irit, Ollech, Jacob E., Lichtenstein, Lev, Banai-Eran, Hagar, Yanai, Henit, Snir, Yifat, Pauker, Maor H., Friedenberg, Adi, Levy-Barda, Adva, Segal, Arie, Broitman, Yelena, Maoz, Eran, Ovadia, Baruch, Golan, Maya Aharoni, Shachar, Eyal, Ben-Horin, Shomron, Perets, Tsachi-Tsadok, Ben Zvi, Haim, Eliakim, Rami, Barkan, Revital, Goren, Sophy, Navon, Michal, Krugliak, Noy, Werbner, Michal, Alter, Joel, Dessau, Moshe, Gal-Tanamy, Meital, Freund, Natalia T., Cohen, Dani, Dotan, Iris“…Subjects enrolled received 2 BNT162b2 (Pfizer/BioNTech) doses. Anti-spike antibody levels and functional activity, anti-TNFα levels and adverse events (AEs) were detected longitudinally. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto